Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06427850

Effect of Topical Tranexamic Acid on Postoperative Drainage in Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF)

The randomized controlled study which compare the efficacy outcomes (reducing blood loss and drainage output in patients) in patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) and received topical tranexamic acid injection in the surgical site to those who received placebo injection.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

Detail : Randomization of Patients for intra-surgical site topical tranexamic acid injection

Objective : To compare the efficacy of topical tranexamic acid (TXA) injection into the surgical wound versus placebo injection in reducing blood loss and drainage output in patients undergoing single-level minimally invasive transforaminal lumbar interbody fusion (MI-TLIF) surgery.

Methods:

Patient: Patients with degenerative spine conditions undergoing single-level MI-TLIF surgery, who received treatment at Ramathibodi Hospital and Chakri Naruebodindra Medical Institute from 2024 to 2027.

Randomization : Patients will be randomly by various block randomization (1:1) was performed using STATA 16.0 to ensure that the two groups were comparable in size and that the sequence of randomization was unpredictable.

Intervention :

Group 1 : Patients in this group will receive an injection of topical tranexamic acid (TXA) into the surgical site(50mg/ml) 10 ml after wound exposure and after wound decompression.

Group 2: Patients in this group will receive a placebo injection (Normal saline 10 ml) into the surgical site after wound exposure and after wound decompression.

Allocation Concealment :

A central randomization service will prepare sealed envelopes labeled with sequence numbers corresponding to the sample size. This method decreasing selection bias in assigning participants to the treatment groups. The envelopes were opened and equipment prepared after anesthesia was administered and before the surgeon began the incision.

Blinding :

The study participants and assessors will be blinded to treatment allocation. The surgeons were blinded by clear fluid as same in 2 groups but if tranexamic acid can be effective to decrease blood loss in intraoperation. So we cannot controlled blinding surgeons.

Primary outcome measurement: postoperative drainage (ml)

Secondary outcome measurement:

calculated total blood loss, intraoperative blood loss, blood transfusion rate, duration of drain maintenance, length of hospital stay, complication of tranexamic acid (TXA) and surgery.

Statistical Analysis:

Demographic Analysis :

For continuous data reported as Mean and Standard Deviation (S.D.) and analyzed by Independent t-test or Mann-Whitney U test.

For categorical data reported as Percentages and analyzed by Chi-square test.

Compare the results of the study:

Postoperative drainage (ml),calculated total blood loss (ml), intraoperative blood loss (mL) , duration of drain maintenance (day), length of hospital stay (day)were report to Mean and Standard Deviation (S.D.) analyzed by Independent t-test or Mann-Whitney U test for continuous data.

Complication of tranexamic acid (TXA) and surgery(%), blood transfusion rate (%) were reported to Percentages and analyzed by Chi-square test. Use STATA 16.0 software for statistical calculations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 30-80 years old
  • Degenerative spine problems including spinal stenosis, disc degeneration, spondylolithesis that indicated for single level MI-TLIF

Exclusion criteria

  • Revision surgery
  • Patients who had high risk of complication from TXA
  • History of seizure, PE, DVT, thromboembolic episode
  • History of TXA allergy
  • Patients who had high risk for bleeding
  • U/D : CKD stage more than IIIb (GFR< 45 ml/min/1.73m2), hepatic disease, bleeding disorder
  • On anticoagulation drug or antiplatelet drug in 7 days before surgery
  • Abnormal coagulation profile (INR > 1.5) or CBC (platelet < 100000)

Treatment and study plan

Tranexamic Acid

Drug

receive an injection of Tranexamic acid into the surgical site

normal saline

Drug

receive an injection of Normal saline into the surgical site

Primary outcomes

  1. postoperative drainage (mL)

    Time frame: 120 hours

    Fluid drainage after operation

Secondary outcomes

  1. calculated total blood loss (mL)

    Time frame: 120 hours

    calculated total blood loss by Gross formular

  2. intraoperative blood loss (mL)

    Time frame: Intraoperative time

    Evaluated by anesthesiologists

  3. duration of drain maintenance (day)

    Time frame: 120 hours

    Duration time of drain insertion to off drain

  4. length of hospital stay (day)

    Time frame: 120 hours

    Duration time of patients stay in hospital

  5. complication of tranexamic acid (TXA) and surgery(%)

    Time frame: 120 hours

    The patients who had complication from tranexamic acid (TXA) and surgery in each group

Study contacts

Contact information is provided by the study sponsor or research team.

Kan Kaewroj, Diploma of Orthopaedics

CONTACT

(+66) 022011589

Thanawan Longsuwan, Doctor of medicine

CONTACT

[email protected]

(+66)892966855

Sponsors and collaborators

Lead sponsor

Thanawan Longsuwan

Other

Registry information

Official study title

Effect of Topical Tranexamic Acid on Postoperative Drainage in Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI-TLIF): A Randomized Controlled Trial

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
May 24, 2024
Registry last updated
May 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.